Skip to content
Madrigal Pharmaceuticals
-
Madrigal expands MASH pipeline with US$1B licensing deal for Arrowhead’s siRNA therapy
Under the agreement, Madrigal will take over the development, manufacturing, and commercialisation of Arrowhead’s investigational therapy, ARO-PNPLA3.
-
Madrigal strikes USD4.4B deal with Suzhou Ribo Life Science to advance liver disease treatments
At the heart of this collaboration sits Ribo’s GalSTAR platform, a specialized system designed to help develop RNA interference therapeutics that target disease-causing genes in liver conditions.